BofA Securities Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $165
BofA Securities analyst Tazeen Ahmad maintains $Ascendis Pharma A/S(ASND.US)$ with a buy rating, and maintains the target price at $165.According to TipRanks data, the analyst has a success rate of 46
European Equities Traded in the US as American Depositary Receipts Fall in Wednesday Trading
European equities traded in the US as American depositary receipts fell Wednesday morning, declining 0.48% to 1,423.09 on the S&P Europe Select ADR Index. From continental Europe, the gainers were led
$100 Invested In This Stock 10 Years Ago Would Be Worth $6,500 Today
Ascendis Pharma (NASDAQ:ASND) has outperformed the market over the past 10 years by 41.19% on an annualized basis producing an average annual return of 51.99%. Currently, Ascendis Pharma has a market
Express News | Morgan Stanley Maintains Equal-Weight on Ascendis Pharma, Raises Price Target to $140
FDA Pushes Review Date For Ascendis Pharma's Hormone Disorder Candidate By Three Months
Tuesday, Ascendis Pharma A/S (NASDAQ:ASND) announced that the FDA extended the review date for TransCon PTH (palopegteriparatide) for adults with hypoparathyroidism.Hypoparathyroidism is an uncommon c
Ascendis Pharma (ASND) Receives a Hold From TD Cowen
Express News | Ascendis Pharma A/S : Jefferies Cuts Target Price to $174 From $175
US Equity Markets Close Higher Tuesday as Producer Prices Rise
US equity markets ended higher Tuesday as the producer price index increased more than expected. * The US Producer Price Index rose 0.5% in April following a downwardly revised 0.1% decrease in March,
Sector Update: Health Care Stocks Rise in Late Afternoon Trading
Health care stocks were higher late Tuesday afternoon, with the NYSE Health Care Index adding 0.5% and the Health Care Select Sector SPDR Fund (XLV) up 0.5%. The iShares Biotechnology ETF (IBB) rose 0
Sector Update: Health Care
Health care stocks were higher late Tuesday afternoon, with the NYSE Health Care Index adding 0.5% and the Health Care Select Sector SPDR Fund (XLV) up 0.3%. The iShares Biotechnology ETF (IBB) rose 0
Ascendis Pharma Says FDA Has Delayed TransCon PTH Review
Ascendis Pharma Says FDA Extending Review Period for NDA
By Ben Glickman Ascendis Pharma said regulators had pushed back the target action date for reviewing its hypoparathyroidism treatment after the company submitted additional information. The Danish b
UPDATE 1-FDA Extends Review of Ascendis Pharma's Hormone Disorder Therapy
Ascendis Pharma Announces Extension of U.S. Food and Drug Administration Review Period for TransCon PTH for Adults With Hypoparathyroidism
- Prescription Drug User Fee Act (PDUFA) goal date extended by three months for further review of submission to August 14, 2024 COPENHAGEN, Denmark, May 14, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND)
Ascendis Pharma Announces 2-Year Results From A Post-hoc Analysis Of Their Phase 3 Pathway Trial Demonstrating Sustained Improvements In Renal Function In Adults With Chronic Hypoparathyroidism Treated With TransCon PTH
Ascendis Pharma A/S (NASDAQ:ASND) today announced 2-year results from a post-hoc analysis of the Company's Phase 3 PaTHway Trial demonstrating significant and sustained improvements in renal function
Ascendis Pharma A/S Clinical And Quality-Of-Life Data For TransCon PTH-Treated Adults With Chronic Hypoparathyroidism To Be Presented At ECE 2024
Ascendis Pharma A/S (NASDAQ:ASND) today announced that new TransCon PTH (palopegteriparatide) data supporting clinical and quality-of-life benefits in adult patients with chronic hypoparathyroidism wi
$100 Invested In Ascendis Pharma 15 Years Ago Would Be Worth This Much Today
Ascendis Pharma (NASDAQ:ASND) has outperformed the market over the past 15 years by 16.63% on an annualized basis producing an average annual return of 28.88%. Currently, Ascendis Pharma has a market
European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading
European equities traded in the US as American depositary receipts started the week off on a positive note, rising 0.42% to 1,380.39 on the S&P Europe Select ADR Index. From continental Europe, the ga
Ascendis Pharma Is Maintained at Overweight by JP Morgan
Ascendis Pharma Is Maintained at Overweight by JP Morgan
Ascendis Pharma Price Target Raised to $170.00/Share From $167.00 by JP Morgan
Ascendis Pharma Price Target Raised to $170.00/Share From $167.00 by JP Morgan